tx 3301 has been researched along with Cerebrovascular Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Annemans, L; Dresse, A; Kurz, X | 1 |
| Cohen, SN | 1 |
2 other study(ies) available for tx 3301 and Cerebrovascular Disorders
| Article | Year |
|---|---|
[An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Belgium; Cerebrovascular Disorders; Cost-Benefit Analysis; Costs and Cost Analysis; Delayed-Action Preparations; Dipyridamole; Disease-Free Survival; Drug Combinations; Drug Costs; Economics, Pharmaceutical; Follow-Up Studies; Humans; Markov Chains; Placebos; Platelet Aggregation Inhibitors; Recurrence; Sensitivity and Specificity; Social Security | 1998 |
Dipyridamole plus aspirin in cerebrovascular disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Research Design; Risk Assessment; Scientific Misconduct; Stroke; Treatment Outcome | 2000 |